ABBVIE: IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
IMBRUVICA plus rituximab demonstrated superior progression-free survival against the chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL)